HX 630

a retinoid X receptor ligand that functions as both an RAR synergist and peroxisome proliferator-activated receptor gamma synergist; structure in first source

Also Known As:

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kagechika, Hiroyuki: 4 articles (01/2015 - 01/2003)
2.	Shudo, Koichi: 4 articles (01/2014 - 01/2003)
3.	Fujiwara, Ikuma: 1 article (01/2015)
4.	Ito, Sadayoshi: 1 article (01/2015)
5.	Iwasaki, Yasumasa: 1 article (01/2015)
6.	Kogure, Naotaka: 1 article (01/2015)
7.	Kudo, Masataka: 1 article (01/2015)
8.	Kure, Shigeo: 1 article (01/2015)
9.	Parvin, Rehana: 1 article (01/2015)
10.	Saito-Hakoda, Akiko: 1 article (01/2015)

Related Diseases

1.	Memory Disorders (Memory Loss) 01/01/2014 - "Co-administration of Am80 (0.5 mg/kg) and HX630 (5 mg/kg) for 17 days significantly improved memory deficits (Morris water maze) in AβPP23 mice, whereas administration of either agent alone produced no effect. " 11/01/2004 - "Memory deficit in rats treated with scopolamine was rescued by several synthetic retinoids, RAR-ligands (Am80, Am555S, Tp80) and an RXR-ligand (HX630). "
2.	Neoplasms (Cancer) 01/01/2015 - "Furthermore, HX630 inhibited tumor growth and decreased Pomc mRNA expression in corticotroph tumor cells in female nude mice in vivo. " 01/01/2015 - "Therefore, we examined the effects of synthetic RXR pan-agonists HX630 and PA024 on the proliferation, apoptosis, ACTH secretion, and pro-opiomelanocortin (Pomc) gene expression of murine pituitary corticotroph tumor AtT20 cells. " 01/01/2003 - "In this study, we applied the class prediction algorithm, which was used in the molecular phenotyping of tumors, for the classification of synthetic retinoids (Am80 and Tp80) and retinoid synergists (HX630, TZ335, and PA024) as all-trans retinoic acid-like, 9-cis retinoic acid-like, and control-like classes. "
3.	Pituitary ACTH Hypersecretion 01/01/2015 - "Thus, these results indicate that RXR agonists, especially HX630, could be a new therapeutic candidate for Cushing's disease. "
4.	Hyperplasia 11/01/2006 - "A new RXR agonist, HX630, suppresses intimal hyperplasia in a mouse blood flow cessation model."

Related Drugs and Biologics

1.	tamibarotene
2.	Retinoids
3.	Tretinoin (Retinoic Acid)
4.	Scopolamine (Hyoscine)
5.	Messenger RNA (mRNA)
6.	Pro-Opiomelanocortin (Proopiomelanocortin)
7.	Ligands
8.	Adrenocorticotropic Hormone (ACTH)
9.	TAC 101